KDR and hepatocellular carcinoma: Two medications in the first line: Sorafenib, a multikinase inhibitor and Lenvatinib, a multitarget tyrosine kinase VEGFR and FGFR inhibitor, are currently used for the treatment of advanced HCC.8, 9, 10 Possible mechanisms inducing resistance to Sorafenib are thought to be autophagy and other pathways11, 12; however, precise mechanisms remain elusive.